Payment overview · 2025
General Payments
$807.31
18 reported records · 7 companies
Healthcare provider profile · identity verified
Ali Hazimeh, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · DEARBORN, MI · NPI 1437413721
Verified facts
What the public records show
CMS Open Payments records show Ali Hazimeh, M.D received $807.31 in general payments during 2025 across 18 reported records.
Stryker Corporation accounted for 67.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $543.23 | 67.3% | 9 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $108.57 | 13.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.09 | 7.4% | 3 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $42.08 | 5.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.11 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.00 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.23 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $807.31 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $244.12 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $163.46 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $163.46 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $135.65 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $108.57 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.09 | 3 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $42.08 | 2 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $17.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
221 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 408 | 83 |
| Eliquis | Apixaban | 221 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 48 |
| Losartan Potassium | Losartan Potassium | 143 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 30 |
| Omeprazole | Omeprazole | 117 | 20 |
| Furosemide | Furosemide | 104 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 99 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 21 |
| Carvedilol | Carvedilol | 91 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 24 |
| Sertraline Hcl | Sertraline Hcl | 83 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 18 |
| Metformin Hcl | Metformin Hcl | 80 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 78 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 14 |
| Lisinopril | Lisinopril | 75 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 12 |
| Famotidine | Famotidine | 57 | 14 |
| Simvastatin | Simvastatin | 55 | suppressed |
| Levetiracetam | Levetiracetam | 54 | 14 |
| Jardiance | Empagliflozin | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 17 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 12 |
| Methocarbamol | Methocarbamol | 41 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Lactulose | Lactulose | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | 12 |
| Gabapentin | Gabapentin | 35 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 21 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | 14 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 14 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $807.31 · 18 records | Stryker Corporation | APTIMA, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, General - Pain Management, LifeVest, Ohtuvayre, PAXLOVID, THINPREP 2000 PROCESSOR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error